AI Summary Orkambi (lumacaftor/ivacaftor) is a combination CFTR modulator for cystic fibrosis with two copies of the F508del mutation and is not specifically indicated to treat cystic fibrosis–associated liver disease.
Medically reviewed.
Orkambi (lumacaftor/ivacaftor) is a prescription combination CFTR modulator. It treats cystic fibrosis (CF) in people who have two copies of the F508del CFTR mutation. It improves the amount and function of the CFTR protein, which helps lung function and overall CF management. People with CF can develop liver disease, but Orkambi is not specifically indicated to treat cystic fibrosis–associated liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Orkambi's role in CF care: how it works, who may be prescribed it, how it is used, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT ORKAMBI TREATMENT
Orkambi is a prescription medicine that combines two drugs: lumacaftor and ivacaftor. Together they act as a CFTR modulator. It treats cystic fibrosis (CF) in people who are homozygous for the F508del CFTR mutation. That means they have two copies of the mutation.
Orkambi improves the amount and function of the CFTR protein. This helps improve breathing and supports overall CF management.
People with CF may develop liver disease. Orkambi is not specifically indicated to treat cystic fibrosis–associated liver disease.
It is one part of routine CF care, along with regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs).
WHO ORKAMBI MAY BE SUITABLE FOR
Your healthcare provider may prescribe Orkambi if you have cystic fibrosis with two copies of the F508del mutation. Genetic testing confirms whether you are eligible for treatment.
It may also be considered if you need CFTR modulator therapy, or if you need long-term management of cystic fibrosis.
Every patient's health profile is different. Treatment decisions are individualized and should be made by a qualified healthcare professional.
ELIGIBILITY OVERVIEW
Orkambi may be considered for people with the following conditions or treatment goals:
Before recommending Orkambi, healthcare providers evaluate several factors, including:
HOW ORKAMBI CAN HELP PEOPLE WITH CF
Orkambi combines two medicines that act on the CFTR protein in different ways. Lumacaftor improves the processing and trafficking of the CFTR protein, which helps more of the protein reach the cell surface. Ivacaftor enhances CFTR channel opening and function, so the protein works better once it is there.
Together, these actions increase chloride transport across epithelial cells. This improves mucus hydration and clearance, which helps improve lung function and reduce disease progression.
For people with cystic fibrosis who have two copies of the F508del mutation, these effects support treatment goals such as better breathing and long-term disease management. Orkambi is not used on its own. Providers use it as part of routine CF care, with regular monitoring such as Liver Function Tests (LFTs), to track how you respond.
HEALTH BENEFITS
Cystic fibrosis involves a defective CFTR protein. Orkambi improves the quantity and function of that protein. Lumacaftor improves how the protein is processed and trafficked, and ivacaftor enhances how the CFTR channel opens and works. This addresses CF at its source.
When CFTR works better, more chloride moves across epithelial cells. This improves mucus hydration and clearance, which helps improve breathing and pulmonary health.
Orkambi helps improve pulmonary function and reduce disease progression. It may also decrease respiratory infections and hospitalizations. Results vary from person to person, so your care team tracks your breathing over time.
CF affects more than one organ, and Orkambi may provide benefits across several of them. This includes people who develop liver disease, but Orkambi is not specifically indicated to treat cystic fibrosis–associated liver disease. Your provider monitors your liver function during treatment.
Orkambi supports your health by improving how the CFTR protein works. This helps mucus clearance, lung function, and daily functioning. It works as part of a full CF care plan, not on its own. Your healthcare professional should start it and monitor it.
TREATMENT PROCESS
Orkambi comes as oral tablets. Oral granules are available for younger children.
The typical adult dose is two tablets every 12 hours. Each tablet contains 200 mg of lumacaftor and 125 mg of ivacaftor. Your provider adjusts the dose based on age, body weight, liver function, and other medicines. Pediatric dosing varies by age and formulation.
Take Orkambi with fat-containing food about every 12 hours. Always take it exactly as your healthcare provider directs.
Orkambi is long-term, ongoing therapy. It is typically lifelong in eligible people with cystic fibrosis. Do not stop taking it without first talking to your healthcare provider.
Store Orkambi at room temperature, away from moisture and heat.
Your provider will regularly check your liver function tests, blood pressure, and breathing. Children may also need eye exams. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Orkambi (lumacaftor/ivacaftor) helps people with cystic fibrosis by improving how the defective CFTR protein works. It helps improve lung function and may decrease respiratory infections and hospitalizations. Results vary from person to person.
As with any medication, Orkambi may cause side effects. Shortness of breath can happen, especially when starting therapy. Elevated liver enzymes can also occur, so your healthcare provider will monitor your liver function throughout treatment and decide whether Orkambi remains a suitable option for you.
BENEFITS
Cystic fibrosis involves a defective CFTR protein. Orkambi combines two medicines to address this. Lumacaftor improves how the protein is processed and trafficked. Ivacaftor enhances CFTR channel opening and function. Together, they improve the quantity and function of CFTR protein and increase chloride transport across epithelial cells.
Better CFTR function improves mucus hydration and clearance. This helps improve pulmonary function. Results vary from person to person, and your care team monitors your breathing over time.
Orkambi may decrease respiratory infections and hospitalizations. It is part of routine CF care, which also includes airway clearance and infection prevention.
By reducing pulmonary exacerbations, Orkambi may help you stay well enough to carry out daily activities. It works best alongside the rest of your CF routine, such as airway clearance, good nutrition, and hydration.
Your healthcare provider will discuss the potential benefits and risks before treatment. They will also provide ongoing support, including liver function monitoring, to help ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of your care alongside Orkambi. Your care team may advise changes in nutrition, airway clearance, and daily CF care.
These habits can support how your body responds to treatment.
Areas that may support treatment:
COMMON QUESTIONS
Orkambi (lumacaftor/ivacaftor) treats cystic fibrosis (CF) in people who have two copies of the F508del CFTR mutation. It is a prescription combination CFTR modulator, which means it targets the defective CFTR protein behind CF. It helps improve the amount and function of that protein, supporting breathing and overall CF management. Orkambi is one part of routine CF care. Ask your healthcare professional whether it fits your situation and treatment goals.
No. Orkambi is not specifically indicated to treat cystic fibrosis–associated liver disease. People with cystic fibrosis may develop liver disease, so your healthcare provider monitors your liver function during treatment. Elevated liver enzymes can occur with Orkambi, and regular liver function tests help your care team track them. If you have liver concerns, talk with your provider or a liver specialist about the best care plan for you.
Orkambi helps improve lung function, and it may decrease respiratory infections and hospitalizations. Lumacaftor improves processing and trafficking of the CFTR protein, and ivacaftor enhances CFTR channel opening. Together they improve mucus hydration and clearance and help reduce disease progression. Results vary from person to person. Your healthcare professional can explain what to expect and how your response will be monitored.
Take Orkambi with fat-containing food about every 12 hours. The typical adult dose is two tablets every 12 hours, and oral granules are available for younger children. Your provider adjusts the dose based on age, body weight, liver function, and other medicines, and pediatric dosing varies. Always take Orkambi exactly as directed, and ask your healthcare provider or pharmacist if you have questions about your schedule.
Common side effects of Orkambi include shortness of breath, especially when starting therapy, headache, nausea, diarrhea, and elevated liver enzymes. Not everyone has these effects. Your healthcare provider will discuss the potential benefits and risks before treatment and monitor you during it. Report any side effects or unusual symptoms to your provider, and do not stop taking Orkambi without talking to them first.
Your healthcare provider regularly checks your liver function tests, blood pressure, and breathing while you take Orkambi. Children may also need eye exams. Monitoring matters because elevated liver enzymes can occur, and your provider uses the results to decide whether Orkambi remains a suitable option. Ask your care team how often you will need these checks and what each one involves.
Orkambi is usually long-term, ongoing therapy, and it is typically lifelong in eligible people with cystic fibrosis. It helps maintain CFTR function and slow disease progression. Do not stop taking Orkambi without first talking to your healthcare provider. If side effects or other concerns make you consider stopping, discuss them with your care team so they can adjust your plan safely.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
